Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional)

The Institutional Development Award (IDeA) program develops biomedical research capacity in states that have historically received low levels of NIH funding (IDeA states). The IDeA Clinical & Translational Research (CTR) program supports two programmatic tracks to build clinical and translational (C&T) research capacity to enable research on diseases and health challenges prevalent in IDeA states. IDeA CTR Development (CTR-D) awards focus on C&T research workforce development and infrastructure enhancement at health research organizations with limited clinical research capacity in IDeA states. IDeA CTR Network (CTR-N) awards support statewide (or multi-state) networks of health research organizations to expand existing infrastructure, develop the research workforce to enhance the network organization's ability to design and implement competitive C&T research programs, and coordinate clinical research activities state-wide and/or across IDeA states.This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.

Eligibility Criteria for Lead and Partner OrganizationsEvery organization in the application must be either a Lead or a Partner–no organization can be both.Every organization in the application must be in an IDeA-eligible state.There are strict limits to avoid overlap:Each IDeA-eligible state can only have one active IDeA-CTR-type (IDeA-CTR, CTR-N, or CTR-D) award at a time.An organization can only be involved in one IDeA-CTR-type award at a time.Organizations may not serve as a lead, partner or otherwise participate with an active Clinical and Translational Science Award (CTSA). Organizations must meet all eligibility rules at the time of application submission and award.Additional Eligibility Criteria for Lead OrganizationsTo apply as the lead, the organization must:Already have externally-funded clinical and translational (C&T) research.Additional Eligibility Criteria for Partner OrganizationsTo participate as a partner, the organization mustBe in the same state or multi-state region as the lead organization.Note:Active awards include awards in no-cost extension (NCE).An organization that currently leads an active IDeA-CTR-type award may submit a new application if substantial changes to the CTR are proposed. If the new application is funded, the current award will be administratively ended before the new award begins.

All accepted applications are reviewed for scientific and technical merit by an appropriate initial review group and by a national advisory council. The goal of NIGMS funding policies is to maximize the scientific impact of investments in investigator-initiated biomedical research to drive fundamental scientific discoveries that advance understanding of human health and disease. To address this goal, the Institute strives to support a broad portfolio of research grants of high scientific and technical merit, as determined by peer review, in its mission areas. However, in deciding to fund any application, NIGMS staff also considers other factors, including (consistent with applicable law): the breadth of the Institute�s research portfolio; approaches, and investigators; the total amount of funding available to the investigator; the priority of the research area for the Institute�s mission; Early-stage investigator status; At-risk investigator status?;? and whether the PI would have more than one NIGMS funded R01 (including multi-PI R01s). Because these factors are considered, NIGMS does not have a �payline� or strict cutoff in scores that it will fund. It is important to understand that even applications with outstanding scores might not be funded if the investigator already has substantial other support. Because NIGMS prioritizes funding for meritorious investigators who otherwise would not have support over providing additional grants to already well-funded...